SS 40 - Hem 2: New Protocols, New Paradigms: Clinical Trials Shaping the Future of Hematologic RT

Presentations

• 02:30pm - 02:40pm PT

  Phase II Trial of 'Re-Priming' Radiation Therapy for Relapsed/Refractory Non-Hodgkin Lymphoma Patients in Incomplete Response after Chimeric Antigen Receptor T-cell (CAR-T) Therapy

  Speaker: Kiran Kumar, MD, MBA - UT Southwestern Medical Center, Dallas
• 02:30pm - 03:45pm PT

  Hem 2: New Protocols, New Paradigms: Clinical Trials Shaping the Future of Hematologic RT

  Speaker: Pranshu Mohindra, MD, MMM - University Hospitals Seidman Cancer Center, Cleveland, OH, Cleveland
• 02:40pm - 02:50pm PT

  Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study

  Speaker: Alexandra Dreyfuss, MD, MS - University of Miami - Sylvester Cancer Center, Coral Gables
• 02:50pm - 03:00pm PT

  Prospective Study of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cells for Relapsed/Refractory B-Cell Lymphomas

  Speaker: Brandon Imber, MD, MS - Memorial Sloan Kettering Cancer Center, New York
• 03:00pm - 03:10pm PT

  Differential Impact of Total Body Irradiation- vs. Chemotherapy-Based Myeloablative Conditioning on Oral Microbiota and Mucositis after Allogeneic Transplantation

  Speaker: Maryam Ebadi, MD - University of Washington, Seattle
• 03:10pm - 03:20pm PT

  Updated Results of RESTART Protocol (<em>R</em>adioth<em>E</em>rapy bridging and con<em>S</em>olida<em>T</em>ion for C<em>AR-T</em>) in Large B-cell Lymphoma

  Speaker: George Mikhaeel, MD, MBBS - Guy's and St. Thomas' NHS Foundation Trust, London